Complete Remissions Following Immunotherapy or Immuno-oncology Combinations in Cancer Patients: the MOUSEION-03 Meta-analysis

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2023 Jan 12

PMID 36633661

Authors

Matteo Santoni

Alessandro Rizzo

Jakub Kucharz

Veronica Mollica

Matteo Rosellini

Andrea Marchetti

Elisa Tassinari

Fernando Sabino Marques Monteiro

Andrey Soares

Javier Molina-Cerrillo

Enrique Grande

Nicola Battelli

Francesco Massari

Affiliations

Soon will be listed here.

Abstract

Background: Immunotherapy has determined unprecedented long-term responses in several hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis to determine the possibility of achieving complete remissions (CR) with immunotherapy or immuno-oncology combinations in cancer patients.

Methods: The primary endpoint was to assess the incidence of CR in cancer patients receiving immune checkpoint inhibitors (ICIs) alone or in combination with other agents versus control treatments. The pooled odds ratio (OR) and 95% confidence interval (CI) for CR rate were extracted.

Results: A total of 12,130 potentially relevant trials were identified; 5 phase II and 80 phase III randomized studies (37 monotherapies and 48 combinations) and 49,425 cancer patients were included. The most frequent types of malignancies were non-small cell lung cancer (n = 14,249; 29%), urothelial cancer (n = 6536; 13%), renal cell carcinoma (n = 5743; 12%), and melanoma (n = 2904; 6%). In patients treated with immunotherapy (as monotherapy or in combination with other anticancer agents), the pooled OR was 1.67 (1.52-1.84). The highest OR was registered by immune-based combinations with two ICIs (3.56, 95% CI 1.28-9.90).

Conclusions: To the best of the authors' knowledge, no comprehensive meta-analysis on the use of ICIs and ICI-based combinations in solid tumors to systematically investigate the probability to achieve CR has been published so far. Although CR is not a common event in several cancer patients receiving immunotherapy, the MOUSEION-03 suggests that the use of ICIs may significantly increase the chance of achieving CR in comparison with control treatments.

Citing Articles

Diagnostic and prognostic values of NSCLC patients with or without obstructive pneumonia after sleeve lobectomy.

Huang Y, Zhang L, Zhang W, Lv N, Wang T Front Cell Infect Microbiol. 2024; 14:1474998.

PMID: 39735257 PMC: 11682716. DOI: 10.3389/fcimb.2024.1474998.

Adverse reactions of immune checkpoint inhibitors combined with angiogenesis inhibitors: A pharmacovigilance analysis of drug-drug interactions.

Ren X, Deng L, Dong X, Bai Y, Li G, Wang Y Int J Immunopathol Pharmacol. 2024; 38:3946320241305390.

PMID: 39660594 PMC: 11632882. DOI: 10.1177/03946320241305390.

Combinatorial treatment with traditional medicinal preparations and VEGFR-tyrosine kinase inhibitors for middle-advanced primary liver cancer: A systematic review and meta-analysis.

Yu H, Hu J, Han B, Du Y, Chen S, Chen X PLoS One. 2024; 19(11):e0313443.

PMID: 39576764 PMC: 11584121. DOI: 10.1371/journal.pone.0313443.

An Active Trend of Immunotherapy Combination Regimen as Second-Line Therapy Towards Advanced Biliary Tract Cancer.

Weng H, Zeng P, Chen Y, Xu Q, Ying J Clin Med Insights Oncol. 2024; 18:11795549241272469.

PMID: 39421650 PMC: 11483792. DOI: 10.1177/11795549241272469.

Adverse reactions of immune checkpoint inhibitors combined with Proton pump inhibitors: a pharmacovigilance analysis of drug-drug interactions.

Ren X, Li L, Chen Y, Cui X, Wan R, Wang Y BMC Cancer. 2024; 24(1):1193.

PMID: 39334098 PMC: 11438026. DOI: 10.1186/s12885-024-12947-7.

References

Massari F, Rizzo A, Mollica V, Rosellini M, Marchetti A, Ardizzoni A . Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. Eur J Cancer. 2021; 154:120-127. DOI: 10.1016/j.ejca.2021.06.015. View

Mittendorf E, Zhang H, Barrios C, Saji S, Jung K, Hegg R . Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase.... Lancet. 2020; 396(10257):1090-1100. DOI: 10.1016/S0140-6736(20)31953-X. View

Sugawara S, Lee J, Kang J, Kim H, Inui N, Hida T . Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2021; 32(9):1137-1147. DOI: 10.1016/j.annonc.2021.06.004. View

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D . Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019; 394(10212):1929-1939. DOI: 10.1016/S0140-6736(19)32222-6. View

Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazieres J . A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol. 2020; 15(10):1657-1669. DOI: 10.1016/j.jtho.2020.06.015. View

Winer E, Lipatov O, Im S, Goncalves A, Munoz-Couselo E, Lee K . Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(4):499-511. DOI: 10.1016/S1470-2045(20)30754-3. View

Pujade-Lauraine E, Fujiwara K, Ledermann J, Oza A, Kristeleit R, Ray-Coquard I . Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021; 22(7):1034-1046. DOI: 10.1016/S1470-2045(21)00216-3. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Nishiyama H, Yamamoto Y, Sassa N, Nishimura K, Fujimoto K, Fukasawa S . Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. Int J Clin Oncol. 2019; 25(1):165-174. PMC: 6946746. DOI: 10.1007/s10147-019-01545-4. View

10.

Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F . Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018; 19(11):1468-1479. DOI: 10.1016/S1470-2045(18)30673-9. View

11.

Choueiri T, Powles T, Burotto M, Escudier B, Bourlon M, Zurawski B . Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021; 384(9):829-841. PMC: 8436591. DOI: 10.1056/NEJMoa2026982. View

12.

Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A . First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397(10272):375-386. DOI: 10.1016/S0140-6736(20)32714-8. View

13.

Powles T, van der Heijden M, Castellano D, Galsky M, Loriot Y, Petrylak D . Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020; 21(12):1574-1588. DOI: 10.1016/S1470-2045(20)30541-6. View

14.

Rodriguez-Abreu D, Powell S, Hochmair M, Gadgeel S, Esteban E, Felip E . Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021; 32(7):881-895. DOI: 10.1016/j.annonc.2021.04.008. View

15.

Herzyk D, Haggerty H . Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies. AAPS J. 2018; 20(2):28. DOI: 10.1208/s12248-017-0184-3. View

16.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

17.

Bergerot P, Lamb P, Wang E, Pal S . Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence. Mol Cancer Ther. 2019; 18(12):2185-2193. DOI: 10.1158/1535-7163.MCT-18-1399. View

18.

Shitara K, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K . Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10):1571-1580. PMC: 7489405. DOI: 10.1001/jamaoncol.2020.3370. View

19.

Vanneman M, Dranoff G . Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012; 12(4):237-51. PMC: 3967236. DOI: 10.1038/nrc3237. View

20.

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View